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Abstract
Retinopathy of prematurity (ROP) is a leading cause of blindness in children worldwide due to increasing survival rates of
premature infants. Initial suppression, followed by increased production of the retinal vascular endothelial growth factor-A
(VEGF) expression are key events that trigger the pathological neovascularization in ROP. Fatty acid binding protein 4
(FABP4) is an intracellular lipid chaperone that is induced by VEGF in a subset of endothelial cells. FABP4 exhibits a pro-
angiogenic function in cultured endothelial cells and in airway microvasculature, but whether it plays a role in modulation
of retinal angiogenesis is not known. We hypothesized that FABP4 deficiency could ameliorate pathological retinal
vascularization and investigated this hypothesis using a well-characterized mouse model of oxygen-induced retinopathy
(OIR). We found that FABP4 was not expressed in retinal vessels, but was present in resident macrophages/microglial cells
and endothelial cells of the hyaloid vasculature in the immature retina. While FABP4 expression was not required for normal
development of retinal vessels, FABP4 expression was upregulated and localized to neovascular tufts in OIR. FABP4
2/2 mice
demonstrated a significant decrease in neovessel formation as well as a significant improvement in physiological
revascularization of the avascular retinal tissues. These alterations in retinal vasculature were accompanied by reduced
endothelial cell proliferation, but no effect on apoptosis or macrophage/microglia recruitment. FABP4
2/2 OIR samples
demonstrated decreased expression of genes involved in angiogenesis, such as Placental Growth Factor, and angiopoietin
2. Collectively, our findings suggest FABP4 as a potential target of pathologic retinal angiogenesis in proliferative
retinopathies.
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Introduction
Retinopathy of prematurity (ROP) has become a leading cause
of blindness in children worldwide due to increasing survival rates
of premature infants[1]. Severe ROP affects 30–40% of infants
born between 23–26 weeks gestational age[2]. Although the
current laser ablation treatment reduces the incidence of blindness
in infants with late-stage ROP, it can lead to other problems, such
as development of abnormal retinal structure, strabismus, glauco-
ma and nystagmus[3–5].
ROP is a biphasic disease that is associated with abnormal
retinal vascular development[1,6]. The first phase of ROP is
characterized by vaso-obliteration and cessation of normal blood
vessel growth in the retina. Suppression of retinal vascular
endothelial growth factor (VEGF)-A expression by relative
hyperoxia is one of the key events that triggers the pathology
associated with phase 1 ROP, which lasts until approximately 30–
32 weeks corrected gestational age. In phase 2 or the proliferative
phase of ROP, increased metabolic activity of the maturing retina
leads to relative hypoxia and increased production of VEGF-A as
well as other angiogenic factors, such as insulin-like growth factor
1 (IGF-1) and erythropoietin (EPO). The key role of VEGF-A in
the pathogenesis of ROP has been underscored in a recent clinical
trial, where intravitreal administration of a VEGF-A-blocking
antibody, bevacizumab, was found to be superior to laser therapy
in infants with severe ROP[7,8]. However, both pre-clinical and
clinical studies have well documented the critical homeostatic and
trophic function of VEGF-A not only on the vasculature but also
on neurons and epithelial cells[9,10]. As intravitreal bevacizumab
administration decreases serum levels of VEGF-A, there are
significant concerns regarding the potential systemic side effects
and long-term outcomes associated with this treatment[11–13].
Fatty acid binding protein 4 (FABP4) is a small molecular
weight intracellular lipid chaperone, which plays an important role
in regulation of lipid and glucose homeostasis as well as
inflammation through its actions in adipocytes and macrophag-
es[14–18]. We have recently reported that FABP4 is also
expressed in a subset of endothelial cells (EC), where its expression
is positively regulated by the VEGF/VEGFR2 and mTORC1
pathways[19–21]. In contrast to pan-endothelial cell markers, such
as CD31, FABP4 expression is restricted to microvascular and
small vascular ECs, which are actively involved in angiogenic
responses. Consistent with this notion, deficiency of EC-FABP4
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proliferation, migration, survival, and morphogenesis through
modulation of several pathways, including eNOS and SCF/c-kit
signaling[19,22]. These findings were recently corroborated in a
transgenic mouse model, where FABP4 knock-out mice were
protected from VEGF-induced airway angiogenesis and inflam-
mation due to the lack of EC-FABP4[23]. Furthermore studies in
human subjects with glioblastoma, the most malignant primary
brain tumor in adults associated with robust angiogenic activity,
revealed FABP4 expression in a subset of ECs, which was not
detected in control specimens[21].
Taken together, these studies have suggested that FABP4 might
enhance pathological angiogenesis, which plays a role in the
pathogenesis of ROP. Thus we hypothesized that genetic
deficiency of FABP4 could ameliorate pathological retinal
neovascularization that occurs in ROP and investigated this
hypothesis using a well-characterized mouse model of oxygen-
induced retinopathy (OIR)[24].
Results
FABP4 is induced during retinal development but is not
required for normal vascular development
To investigate the role of FABP4 in retinal vasculature, we first
characterized the relative expression of FABP4 during the
postnatal developmental stages of the mouse retina. As shown in
Figure 1A, FABP4 is strongly induced in retinal tissues starting at
P5 and peaking at P17, and its level plateaus in mature retinas at
P33. Using immunostaining on retinal flat-mounts and sections,
we did not detect FABP4 expression in developing or mature
retinal vessels, but identified robust FABP4 expression in resident
macrophages/microglias and EC of the hyaloid vasculature
(Figure 1B). As expected, FABP4 was also detected in other non-
neuronal ocular and periocular vascular beds such as the limbal
vessels and ocular muscles capillaries (Figure S1). In the mature
retina, following the complete regression of the hyaloid vessels,
faint and ubiquitous FABP4 immunoreactivity was detected
throughout the retinal layers. Since FABP4 induction reaches its
maximum levels at the time of completion and maturation of the
inner retinal vasculature, FABP4 could play a role during normal
retinal vascularization. To investigate this possibility, we used P7
flat-mount retinas stained for the blood vessel basal membrane
marker, collagen IV, and found a similar percentage of
vascularized area in WT (93.3961.24, n=4) and FABP4
2/2
(90.8362.32, n=5) animals (Figure 1C). Similarly, quantification
of vascular density at P7 did not reveal any difference between WT
(37.8760.70, n=4) and FABP4
2/2 (37.4960.96, n=6) retinas
(Figure 1C). These results demonstrate that FABP4 expression is
not required for normal development of retinal vessels. Further-
more, histological analysis of adult FABP4
2/2 retina showed no
signs of abnormal morphology or thinning (Figure 1D), thus also
demonstrating that FABP4 is not required for development and
survival of the neuroretina.
FABP4 is specifically induced in neovascular tufts in OIR
Our previous studies have demonstrated that FABP4 expression
in EC is strongly upregulated by VEGF-A, a key mediator of
pathological neovascularization in OIR. Therefore we next
determined whether FABP4 expression was upregulated in the
OIR model, where VEGF is dramatically induced by the hypoxic
retinal tissue. Indeed, we observed a rapid and significant increase
in FABP4 mRNA expression in the hypoxic retina at the stage of
most active angiogenic response (P15–P17) (Figure 2A). Western-
blot analysis confirmed induction of FABP4 at the protein level in
OIR (Figure 2B). Contrary to the increased FABP4 expression
observed in the retinal tissue, circulating FABP4 levels were
significantly decreased in mice exposed to OIR (Figure 2C).
Localization of FABP4 expression in OIR flat-mounted retinas co-
stained with the EC marker BS1 revealed FABP4 to be specifically
induced in the neovascular tufts, while normal vessels even closely
located to sites of abnormal neovessels showed no FABP4
immunoreactivity (Figure 2D). The specificity of FABP4 staining
was confirmed by the absence of staining in OIR retina from
FABP4
2/2 animals. Similarly, confocal analysis of FABP4
expression in OIR cryosections demonstrated its specific expres-
sion in pathological neovascular tufts (Figure 3A). Interestingly,
FABP4 was not detected in Iba-1 positive microglia/macrophages
cells associated with the neovascular structures (Figure 3A) but was
clearly detected in the endothelial component of the pathological
tufts as demonstrated by its colocalization with the endothelial cell-
specific marker endomucin (EMCN) (Figure 3B).
Genetic deficiency of FABP4 is protective against
pathological neovascularization in OIR
In light of the role of FABP4 in VEGF-dependent signaling in
EC and its specific induction in the neovasculature, we next
investigated whether FABP4 could regulate pathological vascular
proliferation in the OIR model. As the level of angiogenic response
in the OIR model is tightly regulated by the extent of the retinal
ischemia induced by vaso-obliteration secondary to the hyperoxic
treatment[25], we quantified the avascular areas at P12, time of
maximal capillary drop-out, and at P17, time of maximal
angiogenic response. Lack of FABP4 was associated with a robust
reduction in the areas of pathological neovascularization at P17
when compared to WT controls (Figure 4A and C). Interestingly,
FABP4
2/2 mice displayed a significant increase in percentage of
vaso-obliteration, when compared to WT mice (Figure 3A and B).
There was also a reduction in the central avascular area at P17 in
FABP4
2/2 retinas. Taken together these results suggest that
FABP4 deficiency was not only associated with a reduction in
pathological neovascularization but also led to a significant
improvement in physiological revascularization of the avascular
retinal tissues as demonstrated by the significantly increased slope
of revascularization between P12 and P17 (Figure 4B).
Protective effect of FABP4 deficiency in OIR is not
associated with altered recruitment of macrophages/
microglia
In the OIR model, recruitment and activation of macrophages
are critical components of the pathological angiogenic process as
macrophages can secrete angiogenic cytokines and growth
factors[26,27]. Increased secretion of VEGFA and other pro-
inflammatory cytokines, such as SDF-1, by the hypoxic retinal
tissue leads to robust recruitment and activation of macrophages/
microglia as indicated by the appearance of numerous rounded,
amoeboid cells intensely stained with the specific marker Iba-1
[27](Figure 5). To determine whether changes in macrophage
infiltration could contribute to the reduced retinal neovascular-
ization observed in FABP4
2/2 animals, we quantified the number
of activated macrophages/microglia in P17 retinas. However,
there were no differences in the number of activated macrophage
per retina or the number of macrophages directly in contact with
neovessels in WT versus FABP4
2/2 mice (Figure 5). These results
suggest that, in the OIR model, the protective effect of FABP4
deficiency is not due to reduced macrophage/microglia recruit-
ment or association to the neovascular tufts.
FABP4 Regulates Oxygen-Induced Retinopathy
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with reduced EC proliferation
Our previous studies demonstrated that FABP4 promotes
proliferation and survival of ECs in vitro [19–22]. To determine
whether protective effect of FABP4 deficiency is associated with
reduced EC proliferation or survival, we assessed the index of
proliferation and apoptosis in neovascular tufts stained by BS-1
and PHH-3 as a marker of cell division or activated caspase-3 as a
marker of apoptosis (Figure 6A). We observed a robust reduction
in the number of dividing ECs in FABP4
2/2 retinal neovessels,
but no change in apoptosis suggesting that FABP4 deficiency
reduces the proliferative capacity of ECs without having an effect
on their survival in the OIR model.
FABP4 deficiency modulates the expression of
angiogenesis-associated genes in OIR
To begin to gain mechanistic insights into the effect of FABP4 in
OIR, we analyzed the expression levels of a select group of genes
that are known to play roles in the pathogenesis of OIR by real-
time PCR analysis of total RNA isolated from P15 mouse retinas
Figure 1. FABP4 expression and function during normal retinal development. (A) qPCR quantification of FABP4 mRNA in total retinas from
P1 to P33 WT mice. Results are expressed as RE (relative expression) normalized to housekeeping genes (mean 6 SEM, n=3–4). FABP4 is significantly
induced during the postnatal stage of retinal development. (B) FABP4 distribution was determined on retina flat-mounts and paraffin sections. At P7,
FABP4 expression (red) was not observed in the inner retinal vessels stained by the pan-EC marker EMCN (green). FABP4 was strongly detected in the
vitreal macrophages (arrowheads) and hyaloid endothelial cells (arrows). Paraffin sections of adult retina demonstrate faint, but uniform expression of
FABP4 in all retinal layers. (C) WT and FABP4
2/2 P7 flat-mount retinas were immunostained with Collagen IV to identify the vascular network. (D)
Vascular coverage and density was similar in WT and FABP4
2/2 animals indicating that FABP4 expression is not required for normal retinal
vascularization. (E) Hematoxylin and eosin stained sagittal retinal sections of adult WT and FABP4
2/2 mice showed no morphological anomalies or
degeneration in FABP4
2/2 animals. gcl: ganglion cell layer; ipl: inner plexiform layer; inl: inner nuclear layer; onl: outer nuclear layer; os: outer
segment.
doi:10.1371/journal.pone.0096253.g001
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receptors VEGFR1 and VEGFR2 were significantly upregulated
in WT OIR and were not affected by FABP4 deficiency. In
contrast, we detected a significant alteration in the expression level
of Placental Growth Factor (PlGF), a member of the VEGF family
that binds VEGFR1, which has been shown to stimulate
pathological angiogenesis in multiple tissues including the
retina[28]. During OIR, we observed a robust induction of PlGF
in WT retinas that was significantly blunted in FABP4
2/2
samples. We observed a similar pattern of expression with
Angiopoietin 2 (Ang2) mRNA levels. While Ang1 levels did not
show any significant changes between WT or FABP4
2/2 OIR
samples, Ang2 levels showed a significant increase in WT OIR
and a significant decrease in FABP4-KO OIR as compared to WT
OIR. There were also significant decreases in the mRNA levels of
pan-endothelial cell markers CD31 and cadherin 5 in FABP4
2/2
OIR as compared to WT OIR.
Discussion
In this study we found that genetic deficiency of FABP4
provides significant protection against the development of OIR in
Figure 2. Specific induction of FABP4 in neovessels during OIR. (A) qPCR quantification of FABP4 mRNA in total retinas from P12 to P17 in
control (RA=room air) and OIR WT mice. Results are expressed as RE (relative expression) normalized to housekeeping genes (mean 6 SEM, n=3–4).
FABP4 mRNA is significantly induced during the angiogenic phase of OIR. (B) Quantification of FABP4 protein expression in P17 RA control and OIR
retinas by immunoblot and densitometry analysis (mean 6 SEM, n = 6) confirmed up-regulation of FABP4 expression during pathological
neovascularization. (C) Quantification of circulating FABP4 demonstrated a significant decrease of serum FABP4 levels in OIR P17 WT mice compared
to control room air (RA). Results are presented as mean 6 SEM based on n=3–4 individual animals. (D) FABP4 distribution was determined on P17
retina flat-mounts from OIR animals co-stained with the pan-endothelial marker BS1. FABP4 is expressed in neovascular tufts (arrowheads) and absent
from adjacent normal blood vessels (arrows). Specificity of the FABP4 staining is confirmed using FABP4
2/2 retina. Scale bar is 100 mm.
doi:10.1371/journal.pone.0096253.g002
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2/2 retinas demonstrated decreased
neovascularization, decreased cell proliferation index, and lower
mRNA levels of several genes involved in angiogenic responses as
compared to WT retinas in the OIR model. Remarkably, FABP4
expression was localized primarily to the neovascular tufts and was
absent from normal retinal blood vessels in OIR samples.
We have previously characterized the expression of FABP4 in
the vasculature and reported that FABP4 expression was primarily
confined to the microvascular endothelial cells in several normal
tissues and organs, excluding the normal cerebral and pulmonary
vasculature[19,21]. In this study, we have extended these previous
observations and found that FABP4 is not expressed in the normal
retinal vessels, but is detected primarily in the microglia and
hyaloid vasculature in the postnatal developing retina. FABP4
mRNA levels increased gradually postnatally, reaching the adult
levels by P17. As hyaloid vessels normally regress by this age,
increased expression levels of FABP4 in the mature retina can
likely be accounted by the increase in microglial cells. Consistent
with this notion, in a recent study, FABP4 expression was also
identified in F4/80-positive cells, a marker for microglia and
macrophages, in the adult mouse retina[29]. In addition to
microglial cells, we have noted faint FABP4 immunoreactivity
throughout the adult mouse retina in non-vascular cells, which
may also contribute to the higher expression levels with advancing
age. However, it should be noted that despite the significant
increase in FABP4 mRNA levels in the developing retina, FABP4
protein levels remained below the detection limit by immunoblot
analysis in whole retinal lysates. Thus, FABP4 is expressed at very
low levels in the postnatal normal retina.
In the mouse OIR model, hyperoxia exposure between P7 and
P12 results in vaso-obliteration of retinal vessels, whereas
normoxia exposure between P12 and P17 results in a relative
hypoxic state, thus stimulating release of angiogenic factors, which
leads to pathological retinal neovascularization. Both mRNA and
protein levels of FABP4 were significantly increased in P17 OIR
samples compared to normoxic retina samples. Most notably,
FABP4 expression was confined to the neovascular tufts and was
absent from adjacent normal retinal vessels. Within the patholog-
ical neovessels, FABP4 appears to be specifically induced in ECs as
it co-localized with the EC markers, EMCN and BS1. This pattern
of increased FABP4 expression in OIR closely parallels that of the
key angiogenic factor VEGF and is in accordance with our
previous studies, which demonstrated induction of FABP4 by
VEGF/VEGFR2 pathway in ECs[19]. Since FABP4 appears to
be expressed primarily in areas exposed to high levels of VEGF in
OIR, FABP4 deficiency or inhibition is unlikely to affect the
maintenance or stability of normal retinal vessels as suggested by
the normal development of retinal vasculature in FABP4
2/2 mice.
Moreover, the reduction of pathological neovascularization
observed in FABP4
2/2 retina was associated with a significant
improvement of the physiological revascularization of hypoxic
areas, further supporting the concept that FABP4 deficiency does
not have an adverse effect on growth of normal retinal vasculature.
Consistent with our previous studies, decreased neovasculariza-
tioninFABP4
2/2 micewasassociatedwith reduced proliferation of
ECs, thus implying a role for FABP4 in regulation of angiogenic
responses of ECs in OIR. Analysis of a panel of genes that regulate
angiogenic responses provided further mechanistic insights into
downstream effects of FABP4 in OIR. For example, we found
significant decreases in PlGF and Ang2 mRNA levels in FABP4
2/2
P15 retinas as compared to WT retinas. Although the role of PlGF,
a ligand exclusive to VEGFR1, in angiogenic pathologies is
controversial, current literature clearly implicates PlGF as an
important contributor to retinal neovascularization. PlGF is
expressed by several cell type including microvascular ECs [30]
and has been shown to stimulate proliferation and migration of
retinal ECs in vitro[31]. Sustained intraocular delivery of PlGF led
to vascular leakage and anomalies similar to early diabetic
retinopathy[32]. Moreover, PlGF deficiency caused a similar effect
to that of FABP4 by reducing pathological neovascularization in
OIR without affecting normal retinal vascular development[28,33].
Destabilizing of blood vessels is one of the initial essential processes
during angiogenesis and is also regulated by another key mediator,
Ang 2, which is also expressed at significantly reduced levels in
FABP4
2/2 retinas[34,35]. Similar to our observations with
FABP4
2/2 mice, Ang2 hemi-deficiency is associated with reduced
neovascularization and avascular area in the OIR model[36]. As
both PlGF and Ang-2 are secreted by activated ECs, the angiogenic
effect of FABP4 could be in part due to its modulation of EC
autocrine and/or paracrine signaling. Further studies will be
required to delineate how FABP4 deficiency leads to decreased
expression of these two critical mediators and the exact role of these
modifications in FABP4-related effects in OIR.
FABP4 has recently been identified as a novel adipokine with
potentially important systemic effects[37]. Exogenous administra-
tion of FABP4 was able to induce smooth muscle cell proliferation
and chemokinesis in vitro [38]. Therefore we considered the
possibility that circulating FABP4 could contribute to pathological
retinal neovascularization. Interestingly, we observed a robust
decrease in serum FABP4 levels in P17 pups exposed to OIR.
While postnatal high oxygen is not associated with gross changes
in body weight and organs function (beside the retina), a potential
deleterious effect of hyperoxia exposure on postnatal adipogenesis
and/or adipokines secretion cannot be excluded. This observation
undermines the potential contribution of circulating FABP4 to
retinal pathological neovascularization. Further studies will be
necessary to better determine the mechanisms of secretion and
systemic and/or paracrine actions of FABP4.
During the progression of OIR, retinal hypoxia may initiate
inflammation by direct activation of microglia[39]. In an in vitro
study, FABP4-deficient macrophages were shown to exhibit
decreased inflammatory function with reduced production of
Figure 3. Specific localization of FABP4 in neovascular
endothelial cells. (A) Confocal imaging of neovascular tufts in P17
WT OIR retina flat-mount following immunostaining for FABP4 (red), EC-
specific marker EMCN (green), activated microglia-specific marker Iba1
(white) and DAPI (blue). FABP4 is strongly associated with the
neovascular tufts and absent from the normal vasculature. FABP4 was
not detected in the Iba1- positive cells but co-localized with EMCN-
positive cells. (B) Immunostaining of FABP4 (red) EMCN (green) and
DAPI (blue) in a large neovascular structure followed by confocal
sectioning confirmed FABP4 localization to ECs of pathological
neovessels. Scale bar is 50 mm.
doi:10.1371/journal.pone.0096253.g003
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association with suppressed activity of NF-kB [40]. These previous
observations prompted us to consider the possibility that a reduced
inflammatory response in the FABP4
2/2 retina, mediated by
either decreased accumulation or activation of microglia could
account for the attenuated neovascular responses. However, we
did not detect FABP4 expression in microglia/macrophages
associated to the neovascular tufts in the retina. Furthermore,
we did not detect any differences in the number of activated
microglial cells/macrophages between FABP4
2/2 and WT
retinas. Finally, gene expression analysis of pro-inflammatory
markers such as TNF-aand Arginase-1 showed no significant
differential expression between FABP4
2/2 and WT OIR retinas
(data not shown). However, the lack of a conditional FABP4
2/2
mouse line has hindered our ability to directly address the
contribution of macrophage- versus EC-FABP4 in this study.
In summary, our data demonstrate that FABP4 deficiency
provides protection in OIR in a mouse model. Lack of FABP4
expression in normal retinal vascular ECs makes FABP4 an
attractive target for proliferative retinopathies, including retinop-
athy of prematurity and diabetic retinopathy.
Figure 4. FABP4 deficiency is protective against OIR. (A) Representative FITC-BS1-stained retina flat-mounts from P12 and P17 WT and
FABP4
2/2 mice exposed to hyperoxia. The vaso-obliterated areas are marked in red and the neovascular areas are marked in white. (B) Quantification
of the avascular areas shows increased central vaso-obliteration in FABP4
2/2 retina at P12, which is decreased at P17 (mean 6 SEM, n=7–12 for P12
and n=15–20 for P17), indicating improved physiological revascularization of avascular areas as indicated by increased slope value (m). (C)
Quantification of neovascular area demonstrated a robust inhibition of pathological neovascularization at P17 (mean 6 SEM, n=15–20).
doi:10.1371/journal.pone.0096253.g004
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Animals
Oxygen-induced retinopathy was induced by placing postnatal
(P) 7 mice in 75% 6 2% oxygen for 5 consecutive days, as
previously described[24]. FABP4
2/2 mice on C57BL/6 back-
ground[15] and FABP4
+/+ littermates or C57Bl/6 mice from the
Jackson Laboratories were used in all experiments.
Ethics Statement
The Harvard Medical Area Standing Committee on Animals
approved all animal procedures.
Real-time PCR
Total RNA was isolated from tissue and cells using RNA-bee
solution (IsoText Diagnostic). RNA was reverse-transcribed using
iScript (Biorad) or the High Capacity cDNA Reverse Transcrip-
tion Kit (Applied Biosystems). qPCR reactions were performed
using the SYBR Green Master mix and the ABI Prism 9700
Sequence Detection System (Applied Biosystems) according to the
manufacturer’s instructions. Accurate gene expression was calcu-
lated relative to the housekeeping genes, HPRT1 and PPIA,
according to the DDCt method. Analyzed genes and correspond-
ing primer sequences are listed in Table 1. Primer pair for
Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) was
purchased as validated premix from SABiosciences (Qiagen).
Western blot
WT and FABP4 eyes were dissected under a dissecting
microscope, the retinas were isolated and homogenized in Lysis
Buffer (Cell Signaling). Each sample corresponded to one
individual mouse. Protein concentration was quantified using a
BCA assay (Bio-Rad, Hercules, CA). For western-blot analysis,
identical protein amount was separated by SDS-page under
reducing condition and transferred to Immobilon-P membrane
(Millipore, Bedford, MA). Membranes were incubated overnight
at 4uC with FABP4 (1:1000, ab97963 lot#GR27611-7, Abcam) or
beta-actin (1:1000, Santa-Cruz) antibodies. Then the membrane
was incubated with corresponding secondary antibodies (1:10000,
Jackson ImmunoResearch Laboratories) in 5% milk, 3% BSA in
TBST buffer for 1 hour at room temperature. Signal intensity was
determined by densitometry (Quantity One; Bio-Rad, Hercules,
CA) and normalized to the amount of beta-actin in each sample.
Immunohistochemistry
Whole retinas were dissected and immunostained as previously
described[9]. Briefly, whole retinas were blocked 2 hours with 1%
BSA in PBS containing 0.1 mM CaCl2, 0.1 mM MgCl2 and
0.1 mM MgCl2 and incubated overnight with the appropriate
antibody: Alexa 488-labeled or Alexa 594-labeled isolectin
Bandeiraea simplicifolia 1 (BS1, Invitrogen), anti-Collagen IV
(Abcam) anti-FABP4 (Abcam and LS-B4227 lot#25048, LifeSpan
BioSciences), anti-phospho histone H3 (ser10) (PHH3, Millipore)
or anti-Iba1 (Wako). Primary antibodies are visualized using Cy5-,
Cy3-, Alexa 594 or Alexa 488 conjugated secondary antibodies
(Jackson ImmunoResearch Laboratories) or using a biotinylated
secondary antibody and detected with the Vectastain ABC system
(Vector). Vascular outgrowth, avascular and neovascular area
were measured on BS1 stained and flat-mounted retinas using
Photoshop CS4 as previously described[25]. For confocal analysis,
retina flat-mounts were co-immunolabeled with rabbit-raised anti-
FABP4 (LifeSpan Bioscience), rat-raised anti-endomucin (EMCN)
(Santa Cruz Biotechnology), goat-raised Iba1 (Abcam). Vascular
density at P7 was measured on collagen IV stained retina flat-
mounts and quantified on 6 fields/retina with each field
representing 0.057 mm
2 located midway between the optic disc
and the periphery and away from any main arteries or veins using
Image J software (National Institute of Health). Briefly, blood
vessels stained for collagen IV were distinguished from back-
ground using empirically determined pixel brightness threshold
values that included only blood vessels. The vascular area was
calculated as the number of pixels having a brightness value higher
than the threshold. The mean value was calculated for each
mouse. Quantification of Iba1 positive cells was performed on
Iba1 and BS1 co-stained flat-mounts using 10 fields/retina at a
206 magnification for total number and 5 fields/retina a 406
magnification for cells associated with neovascular tufts. Quanti-
fication of proliferative and apoptotic endothelial cells was
performed blindly on flat-mounted retina co-stained for the
proliferation marker PHH3 and the endothelial marker BS1, or
for the apoptosis marker active caspase-3 and BS1, respectively,
using 6 fields/retina at a 406magnification randomly selected in
the mid-peripheral region. The number of PHH3 or active
caspase-3 positive endothelial cells per fields was quantified and
normalized to the area of neovascular tufts.
Measurement of FABP4 levels in serum
Non-fasting blood of P17 WT control and OIR pups was
collected from the orbital sinus. Serum was prepared by
centrifugation of the clotted blood samples for 10 min at 4uC
and immediately assayed. Serum FABP4 levels were quantified
Figure 5. Protective effect of FABP4 deficiency in OIR is not
associated with changes in macrophage/microglia recruitment.
Activated and neovascular tuft-associated Iba1 positive (red) cells were
quantified on FITC-BS1-stained (green) retina flat-mounts of P17 WT
and FABP4
2/2 OIR mice. There were no significant differences in the
number of macrophages/microglia recruited to hypoxic retina or those
associated with the neovessels (mean 6 SEM, n=9–10).
doi:10.1371/journal.pone.0096253.g005
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PLOS ONE | www.plosone.org 7 May 2014 | Volume 9 | Issue 5 | e96253Figure 6. FABP4 deficiency is associated with reduced proliferation of neovascular tufts and differential expression of
angiogenesis-related genes. (A) Tufts associated PHH3 positive (red) or activated Caspase-3 positive (red) cells were quantified on FITC-BS1-
stained (green) retina flat-mounts of P17 WT and FABP4
2/2 OIR mice. FABP4 deficiency led to a robust reduction in the number of proliferating ECs in
neovascular tufts. No significant difference in the number of apoptotic neovascular EC was observed (mean 6 SEM, n =4–6). (B) Changes in mRNA
levels of selected genes in retinas from P15 WT and FABP4
2/2 OIR or control mice. The relative steady-state mRNA levels were determined by real-
time PCR. Results are presented as mean 6 SD based on 4–6 samples from individual mice collected from 2–3 independent litters. NS: not significant,
a: Comparison of FABP4
2/2 control versus WT control;
b: comparison of WT OIR versus WT control;
c: comparison of FABP4
2/2 OIR versus WT OIR.
doi:10.1371/journal.pone.0096253.g006
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PLOS ONE | www.plosone.org 8 May 2014 | Volume 9 | Issue 5 | e96253using a mouse FABP4 ELISA kit (Circulex) following the
manufacturer’s instructions.
Statistical analysis
Values are expressed as mean 6 SEM (unless specified) and
statistical analysis was performed using an unpaired Student t test
(***: P,0.001, **: P,0.01, *: P,0.05, ns: P.0.05).
Supporting Information
Figure S1 FABP4 expression in ocular tissues. Immuno-
localization of FABP4 in adult (8 weeks old) ocular tissue
confirmed the expression of FABP4 in endothelial cells of the
periorbital muscles vasculature and limbal vessels. Brown fat was
used as positive control and as expected a strong signal was
detected in adipocytes. Scale bar is 100 mm.
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